Novo Nordisk (NYSE:NVO) is one of the most profitable value stocks to buy according to analysts. On July 25, Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use/CHMP adopted a positive opinion, recommending an expansion of the Alhemo (concizumab) label.
This recommendation includes the treatment of severe haemophilia A and moderate or severe haemophilia B in patients without inhibitors. If approved by the European Commission/EC, Alhemo, which is administered via a pen-injector device, will become available to all adult and paediatric patients aged 12 years and older living with these conditions.
An elderly couple receiving insulin from a pharmacist, representing healthcare company’s successful pharmaceutical products.
The positive CHMP opinion is based on results from the Phase 3 explorer8 trial. This study met its primary endpoint and showed that Alhemo prophylaxis reduced spontaneous and traumatic bleeds for patients with haemophilia A and B without inhibitors compared to no prophylaxis. Specifically, Alhemo prophylaxis led to an 86% reduction in treated spontaneous and traumatic bleeds for haemophilia A patients without inhibitors, and a 79% reduction for haemophilia B patients without inhibitors.
Novo Nordisk researches, develops, manufactures, and distributes pharmaceutical products internationally and operates in two segments: Diabetes & Obesity Care and Rare Disease.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
